🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

TYK Medicines clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with TYK Medicines as lead sponsor. Synced 26 Sep 2026
8Current trials
5Recruiting now
2Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

TYK Medicines is the lead sponsor of 8 current clinical trials in our China register. 5 are recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are Enzalutamide and Osimertinib. The most-studied condition is NSCLC.

ClinicalTrials.gov trials by status

  • Recruiting563%
  • Not yet open338%

Trials by phase

  • Phase 1/2450%
  • Phase 1225%
  • Phase 3113%
  • Phase 2113%
01

Clinical trials sponsored by TYK Medicines

8 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
NCT05382728 · ClinicalTrials.gov ↗ · NSCLC, EGFR Activating Mutation
Phase 3 Recruiting 2022-06 China
Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors
NCT06950086 · ClinicalTrials.gov ↗ · HR-positive, HER2-negative Advanced Breast Cancer
Phase 1/2 Recruiting 2024-01 China
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
NCT05948813 · ClinicalTrials.gov ↗ · NSCLC, EGFR Activating Mutation, Brain Metastases
Phase 2 Recruiting 2023-08 China
A Study of TYK-00540 in Adult Patients With Solid Tumors
NCT06246071 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting 2024-01 China
A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors
NCT05866692 · ClinicalTrials.gov ↗ · Solid Tumor, Adult
Phase 1 Recruiting 2023-08 China
Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors
NCT07282873 · ClinicalTrials.gov ↗ · Solid Tumor Malignancies, Malignant Mesothelioma (MM)
Phase 1/2 Not yet open 2026-01 China
Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer(mCRPC)
NCT07104643 · ClinicalTrials.gov ↗ · mCRPC
Phase 1/2 Not yet open 2025-08 China
Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer(mCRPC)
NCT07104617 · ClinicalTrials.gov ↗ · Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase 1/2 Not yet open 2025-08 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in TYK Medicines trials

2 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in TYK Medicines trials

10 conditions
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China85

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in NSCLC

SponsorTrials
Sichuan University3
Allist Pharmaceuticals3
Tubulis2
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)2
Jiangsu Cancer Institute & Hospital2
Ellipses Pharma1
Eikon Therapeutics1
Shanghai Huaota Biopharmaceutical1
Monte Rosa Therapeutics1
Wen-zhao ZHONG1

Sponsors with the most current trials registered for this condition.

06

Questions about TYK Medicines trials

How many clinical trials does TYK Medicines sponsor?

TYK Medicines is the lead sponsor of 8 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are TYK Medicines trials recruiting?

Yes. 5 of its 8 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is TYK Medicines testing?

Its current trials name 2 drugs and biologicals as interventions. The most frequent are Enzalutamide (1) and Osimertinib (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.